NZ Immuno-Oncology Research Review Issue 33
In this issue:
– Adjuvant cemiplimab in high-risk cutaneous SCC
– Reduced-duration adjuvant trastuzumab in HER2-positive breast cancer
– Trastuzumab deruxtecan or ramucirumab + paclitaxel in gastric cancer
– First-line camizestrant for emerging ESR1-mutated advanced breast cancer
– OS with neoadjuvant nivolumab + chemotherapy in NSCLC
– 5-year survival with atezolizumab after chemotherapy in resected NSCLC
– Outcomes of solid organ transplant recipients with advanced cancers receiving ICIs
– Pembrolizumab + axitinib vs. sunitinib for advanced clear-cell RCC
– Optimal treatment duration for metastatic RCC responsive to ICIs
– Statin use in ICI recipients for cancer
– Ipilimumab + nivolumab for pancreatic neuroendocrine neoplasms
Expert contributor
Dr Alvin Tan
Dr Alvin Tan is a consultant medical oncologist at Waikato Hospital and also practices in private at SalutisCare. He is the current Head of Department for Medical Oncology at Waikato Hospital and previous Chair of the Aotearoa New Zealand Advanced Training Subcommittee for Medical Oncology for the Royal Australasian College of Physicians (2023/2024). He completed […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.
